Business Standard

Sunday, February 16, 2025 | 07:50 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Health ministry not to use Itolizumab in clinical protocols for Covid-19

The permission to market the drug was granted for the treatment of cytokine release syndrome in moderate' to severe' Acute Respiratory Distress Syndrome patients due to Covid-19

medicine
Premium

Biocon, has been manufacturing and marketing Itolizumab under brand name ALZUMAb

Press Trust of India New Delhi
The National Task Force on Covid-19 has decided against including Itolizumab drug in clinical management protocols for treating the disease even though the DCGI has approved its "restricted emergency use" in infected patients, official sources said. 

Considering the unmet medical needs in Covid-19, Itolizumab, an already approved drug of Biocon, used for treating psoriasis - a skin condition - was approved for "restricted emergency use" in the treatment of coronavirus by the Drugs Controller General of India (DCGI) recently. 


The permission to market the drug
Topics : Coronavirus

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in